VHCP Management III, LLC
Follow13F filer, CIK 1738053, New York, NY
VHCP Management III, LLC reported $214,180,000 across 17 holdings for the quarter ended 2019-06-30, in a 13F-HR filed 2019-08-13. Its ten largest share positions make up 93.72% of the portfolio.
Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-19-007812
- Period
- 2019-06-30
- Reported value
- $214M
- Holdings
- 17
- Top 10 weight
- 93.72%
- New
- 1
- Sold out
- 0
Part of the filer group Venrock Healthcare Capital Partners III, L.P.
Nimish ShahKoh Bong Y
Stakes and trades reported after 2019-06-30
13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.
- OKUR ONKURE THERAPEUTICS INC: 13G 2,309,559 shares, 5.7% of the class, 13G filed 2026-11-20, 0001231919-26-001621Timeline
Accepted , ingested - ENTX ENTERA BIO LTD: 13G 8,861,763 shares, 5.1% of the class, 13G filed 2026-10-30, 0001738048-26-000079Timeline
Accepted , ingested - LYCA LYCIA THERAPEUTICS INC: 13G 6,850,237 shares, 11.9% of the class, 13G filed 2026-10-30, 0001738048-26-000077Timeline
Accepted , ingested - FLSC FRAZIER LIFE SCIENCES ACQ-A: 13G 700,000 shares, 9% of the class, 13G filed 2026-10-27, 0001738048-26-000075Timeline
Accepted , ingested - XFOR X4 PHARMACEUTICALS INC: 13G/A 7,644,072 shares, 7.6% of the class, 13G/A filed 2026-11-16, 0001738048-26-000100Timeline
Accepted , ingested - VOR VOR BIOPHARMA INC: 13G/A 6,443,619 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000098Timeline
Accepted , ingested - KRRO KORRO BIO INC: 13G/A 1,474,162 shares, 9.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000096Timeline
Accepted , ingested - JBIO JADE BIOSCIENCES INC: 13G/A 3,858,984 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000094Timeline
Accepted , ingested - HELP HELUS PHARMA INC: 13G/A 2,688,175 shares, 3.5% of the class, 13G/A filed 2026-11-16, 0001738048-26-000092Timeline
Accepted , ingested - CBIO CRESCENT BIOPHARMA INC.: 13G/A 2,228,641 shares, 5.9% of the class, 13G/A filed 2026-11-16, 0001738048-26-000090Timeline
Accepted , ingested - ACHV ACHIEVE LIFE SCIENCE INC: 13G/A 5,502,064 shares, 5.2% of the class, 13G/A filed 2026-11-16, 0001738048-26-000088Timeline
Accepted , ingested
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| MISTnew | +2,066,529 | $56.1M |
| AXSMadded | +543,285 | $14M |
| PTGXadded | +263,025 | $3.19M |
| LA JOLLA PHARMACEUTICAL COadded | +248,298 | $2.3M |
| RA PHARMACEUTICALS INCadded | +75,637 | $2.27M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| TRICIDA INCreduced | -360,839 | -$14.2M |
| KALVreduced | -332,746 | -$7.37M |
| KADMON HOLDINGS INCreduced | -965,733 | -$1.99M |
| ORCHARD THERAPEUTICS PLCreduced | -134,778 | -$1.89M |
| BCRXreduced | -352,884 | -$1.34M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q2 2019
Share positions as resolved from 13F-HR 0000950123-19-007812, largest first. % of portfolio is the value over $214,180,000, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| MISTMILESTONE PHARMACEUTICALS IN | 2,066,529 | $56.1M | 26.2% | new | Timeline | ||
| AXSMAXSOME THERAPEUTICS INC. | 1,611,329 | $41.5M | 19.37% | +543,285 | Timeline | ||
| RA PHARMACEUTICALS INCRA PHARMACEUTICALS INC | 670,350 | $20.2M | 9.41% | +75,637 | |||
| KALVKALVISTA PHARMACEUTICALS INC | 637,884 | $14.1M | 6.6% | -332,746 | Timeline | ||
| ObsEva SAObsEva SA | 1,159,789 | $13.1M | 6.12% | 0 | |||
| PTGXPROTAGONIST THERAPEUTICS INC | 1,072,348 | $13M | 6.06% | +263,025 | Timeline | ||
| LA JOLLA PHARMACEUTICAL COLA JOLLA PHARMACEUTICAL CO | 1,251,898 | $11.6M | 5.41% | +248,298 | |||
| TRICIDA INCTRICIDA INC | 289,746 | $11.4M | 5.34% | -360,839 | |||
| BCRXBIOCRYST PHARMACEUTICALS INC | 2,708,207 | $10.3M | 4.79% | -352,884 | Timeline | ||
| ORCHARD THERAPEUTICS PLCORCHARD THERAPEUTICS PLC | 676,252 | $9.46M | 4.42% | -134,778 | |||
| MARINUS PHARMACEUTICALS INCMARINUS PHARMACEUTICALS INC | 1,258,964 | $5.22M | 2.44% | 0 | |||
| KINIKSA PHARMACEUTICALS LTDKINIKSA PHARMACEUTICALS LTD | 312,320 | $4.23M | 1.97% | -15,457 | |||
| BELLEROPHON THERAPEUTICS INCBELLEROPHON THERAPEUTICS INC | 2,417,227 | $1.45M | 0.68% | 0 | |||
| KADMON HOLDINGS INCKADMON HOLDINGS INC | 422,141 | $870K | 0.41% | -965,733 | |||
| CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL | 66,667 | $819K | 0.38% | 0 | |||
| GEMPHIRE THERAPEUTICS INCGEMPHIRE THERAPEUTICS INC | 798,066 | $646K | 0.3% | -71,472 | |||
| YUMANITY THERAPEUTICS INCYUMANITY THERAPEUTICS INC | 221,267 | $216K | 0.1% | -501,623 |
How Q2 2019 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0000950123-19-007812 | base | 2019-08-13 | acceptance time not in the bulk data set |